FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHA
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section

## NGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GIN JERRY B				2. Issuer Name <b>and</b> Ticker or Trading Symbol  VistaGen Therapeutics, Inc. [ VTGN ]							(Ch	eck all applic	r	10% Ov	ner		
(Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 05/23/2019								Officer below)	(give title	Other (s below)	pecify
(Street) SOUTH FRANCI (City)	SCO C.		94080 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	e) <mark>X</mark> Form fi Form fi	Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tab	le I - Non-	Deriva	ative	Sec	curities	s Ac	quired, D	ispo	osed o	f, or Be	neficial	y Owned			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date		Date,	Transaction Disposed Code (Instr. 5)			urities Acquired (A) or led Of (D) (Instr. 3, 4 and led Of (D) (Instr. 3) and led Of (D)		Beneficia Owned F Reported	s Fo ally (D) ollowing (I)	Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	<u> </u>	Amount			Transact (Instr. 3 a				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	ate, Tr	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cc	ode	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1	05/23/2019			A		50,000		(1)	05/2	23/2029	Common Stock	50,000	\$0	50,000	D	

## **Explanation of Responses:**

1. 25% of the Shares subject to the Option reported herein shall vest on Vesting Start Date May 23, 2019, and 1/36th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the Vesting Start Date thereafter.

/s/ Jerrold D. Dotson, Attorney- 05/28/2019 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.